BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 29562725)

  • 1. Genetic and Epigenetic Regulation in Nonalcoholic Fatty Liver Disease (NAFLD).
    Del Campo JA; Gallego-Durán R; Gallego P; Grande L
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics and epigenetics of NAFLD and NASH: Clinical impact.
    Eslam M; Valenti L; Romeo S
    J Hepatol; 2018 Feb; 68(2):268-279. PubMed ID: 29122391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and epigenetic factors determining NAFLD risk.
    Jonas W; Schürmann A
    Mol Metab; 2021 Aug; 50():101111. PubMed ID: 33160101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA Methylation in Nonalcoholic Fatty Liver Disease.
    Hyun J; Jung Y
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease.
    Li YY
    World J Gastroenterol; 2012 Dec; 18(45):6546-51. PubMed ID: 23236228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and epigenetic mechanisms of NASH.
    Eslam M; George J
    Hepatol Int; 2016 May; 10(3):394-406. PubMed ID: 26683320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential epigenetic mechanism in non-alcoholic Fatty liver disease.
    Sun C; Fan JG; Qiao L
    Int J Mol Sci; 2015 Mar; 16(3):5161-79. PubMed ID: 25751727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease.
    Kitamoto T; Kitamoto A; Ogawa Y; Honda Y; Imajo K; Saito S; Yoneda M; Nakamura T; Nakajima A; Hotta K
    J Hepatol; 2015 Aug; 63(2):494-502. PubMed ID: 25776890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic predisposition in nonalcoholic fatty liver disease.
    Sookoian S; Pirola CJ
    Clin Mol Hepatol; 2017 Mar; 23(1):1-12. PubMed ID: 28268262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic backgrounds in nonalcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Itoh Y
    Clin J Gastroenterol; 2018 Apr; 11(2):97-102. PubMed ID: 29492830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition.
    Mwinyi J; Boström AE; Pisanu C; Murphy SK; Erhart W; Schafmayer C; Hampe J; Moylan C; Schiöth HB
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Mar; 1862(3):314-323. PubMed ID: 27993651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis.
    Dongiovanni P; Meroni M; Longo M; Fargion S; Fracanzani AL
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variation in long noncoding RNAs and the risk of nonalcoholic fatty liver disease.
    Sookoian S; Rohr C; Salatino A; Dopazo H; Fernandez Gianotti T; Castaño GO; Pirola CJ
    Oncotarget; 2017 Apr; 8(14):22917-22926. PubMed ID: 28206970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association of single nucleotide polymorphism of SIRT1 and APOC3 with nonalcoholic fatty liver disease].
    Song X; Song C; Fan L; Ma Q; Mao J; Xu W; Li X
    Wei Sheng Yan Jiu; 2017 Jul; 46(4):527-532. PubMed ID: 29903170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.
    Kawaguchi T; Shima T; Mizuno M; Mitsumoto Y; Umemura A; Kanbara Y; Tanaka S; Sumida Y; Yasui K; Takahashi M; Matsuo K; Itoh Y; Tokushige K; Hashimoto E; Kiyosawa K; Kawaguchi M; Itoh H; Uto H; Komorizono Y; Shirabe K; Takami S; Takamura T; Kawanaka M; Yamada R; Matsuda F; Okanoue T
    PLoS One; 2018; 13(1):e0185490. PubMed ID: 29385134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease.
    Dongiovanni P; Valenti L
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28714900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
    Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
    Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.